Serious & sometimes fatal hypersensitivity reactions. Permanently discontinue if hypersensitivity cannot be ruled out. Lactic acidosis & severe hepatomegaly w/ steatosis. Closely monitor hepatic function w/ clinical & lab follow-up for at least several mth in patients who discontinue treatment & are coinfected w/ HIV-1 & HBV. Patients w/ or w/ no known risk factors for liver diseases. Immune reconstitution syndrome; fat redistribution/accumulation; risk of CHD. Emergence of lamivudine-resistant HBV. Patients w/ CrCl <50 mL/min. Contraindicated in hepatic impairment. Pregnancy. Do not breastfeed during treatment. Ped <18 yr.